Exploració per autor "Molto, Jose"
Ara es mostren els items 1-3 de 3
-
Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Clotet, Bonaventura; Garolera, Maite; Muñoz Moreno, Jose A.; Fumaz, Carmina R.; Prats, Anna; Ferrer, Maria J.; Negredo, Eugènia; Pérez Álvarez, Nuria; Molto, Jose; Gómez Melis, Guadalupe (2010-06)
Article
Accés restringit per política de l'editorialBecause interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectional study ... -
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
Santos, Julia; Clotet, Bonaventura; Ramón Santos, José; Negredo, Eugènia; Massanella, Marta; Puig, Jordi; Pérez Álvarez, Nuria; Gallego-Escuredo, Jose Miguel; Villarroya, Joan; Villarroya, Francesc; Molto, Jose (2010-05-01)
Article
Accés obertBACKGROUND: Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased ... -
Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study
Echeverria, Patricia; Bonjoch, Anna; Puig Batalla, Jorge; Molto, Jose; Paredes, Roger; Sirera, Guillem; Ornelas, Arelly; Pérez Álvarez, Nuria; Clotet, Bonaventura; Negredo, Eugènia (2014-02-04)
Article
Accés obertBackground: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naive patients. However, data on the switching ...